Heartflow, Inc. (HTFL) – What Are Investment Firms Thinking About This Stock?

Heartflow, Inc. (NASDAQ:HTFL) has been given an average recommendation of “Moderate Buy” by the twelve research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $46.25.

A number of brokerages have issued reports on HTFL. Robert W. Baird set a $45.00 target price on shares of Heartflow in a research report on Friday, August 14th. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Canaccord Genuity Group raised their price objective on shares of Heartflow from $45.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th.

Heartflow Stock Performance

Heartflow stock opened at $49.74 on Wednesday. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of -27.18 and a beta of 2.73. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $54.32. The stock’s fifty day moving average is $45.02 and its two-hundred day moving average is $34.50.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business had revenue of $64.08 million during the quarter. The firm’s revenue was up 47.7% on a year-over-year basis. As a group, sell-side analysts forecast that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling at Heartflow

In other Heartflow news, CEO John Farquhar sold 3,890 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $50.00, for a total transaction of $194,500.00. Following the sale, the chief executive officer owned 321,914 shares in the company, valued at approximately $16,095,700. This represents a 1.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 19,682 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $50.15, for a total value of $987,052.30. Following the completion of the sale, the insider owned 79,956 shares in the company, valued at $4,009,793.40. This represents a 19.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 265,205 shares of company stock worth $12,245,527. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Heartflow by 75.1% during the third quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after buying an additional 275 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Heartflow during the second quarter worth approximately $53,000. Essential Partners LLC acquired a new stake in Heartflow during the first quarter worth approximately $57,000. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the 4th quarter worth approximately $72,000. Finally, Valeo Financial Advisors LLC purchased a new stake in Heartflow in the 3rd quarter worth approximately $213,000.

About Heartflow

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow.